New York, United States
Envisagenics is a pioneering biotech company established in 2014 as a spinout of Cold Spring Harbor Laboratory. With a mission to simplify biomedical data and expedite therapeutic development, Envisagenics employs cutting-edge Artificial Intelligence and RNA sequencing analytics. Their focus on RNA splicing analytics addresses the therapeutic needs of over 30 million Americans affected by genetic diseases and cancers, many of which are linked to splicing errors.
The company's flagship technology, SpliceCore, is a cloud-based platform that predicts drug targets and biomarkers using AI-driven splicing discovery from RNA-seq data. By efficiently identifying splicing errors and drug targets, Envisagenics offers a transformative approach that significantly reduces the time, cost, and risk associated with traditional drug development.
In its recent $25.00M Series B funding round, Envisagenics attracted investment from leading firms such as Third Kind Venture Capital, Bristol-Meyers Squibb, New York Ventures of Empire State Development, and Red Cell Partners. This backing underscores investor confidence in Envisagenics' innovative contributions to the AI and biotechnology industries.
